放线菌素23-21对裸小鼠人鼻咽癌细胞系移植瘤和人胃癌细胞系移植瘤的抑制作用

放线菌素23-21属放线菌素类抗癌抗生素,由浅黄色链霉菌产生,该菌从中国福州土壤样品中分离得到。采用裸小鼠人鼻咽癌细胞系(CNE-2Z)和人胃癌细胞系(MGc-803)两种移植模型观察了放线菌素23-21的作用。放线菌素23—21 50μg/kg,对CNE-27移植瘤和MGc803移植瘤的抑制率分别为58.4%(P<0.05)和68.7%(P<0.05)。肿瘤生长曲线显示,治疗组肿瘤生长缓慢。电镜检查,治疗组瘤细胞可见核仁分离和微球体形成。提示放线菌素23-21可能有抑制核仁rRNA合成的作用。在有效剂量下,未见重要脏器病理改变。

INHIBITORY EFFECTS OF ACTINOMYCIN 23-21 ON TRANSPLANTED TUMORS OF HUMAN NASOPHARYNGEAL CARCINOMATOUS CELLS AND GASTRIC CARCINOMATOUS CELLS IN NUDE MICE

Actinomycin 23-21 ( ACT 23-21 ) is an anticancer antibiotic of Actinmycines. This antibiotic was produced from soil Streptomyces flaveolus which was isolated and obtained from soil samples in Fuzhou, China.The effects of ACT 23-21 were observed on using 2 transplanted models of human nasophryangeal carcinomatous cells ( CNE-2Z ) and human gastric carcinomatous cells ( MGc-803 ) in nude mice. At ACT 23-21 50μg/kg, the inhibition rate for transplanted tumors of CNE-2Z and MGc-803 were 58.4% (P<0.05)and 68.7%(P<0.05 ) , respectively. Tumor growth curves showed that the tumor growth was slow in treated group. Under electron microscopy, the nucleolar segregation and formation of microspheres were found in the cancer cells of treated group. The ultrastructural changes suggest that ACT 23-21 probably possesses an inhibitory effect on synthesis of nucleolar rRNA. Under effective dose, no pathologic changes were found in the important organs.